Hansoh Pharma, a top-ranked pharmaceutical company driven by innovation, headquartered in Greater China, is committed to improving human health through continuous innovation, focusing mainly on the fields of oncology, anti-infections, CNS diseases, metabolic diseases, as well as autoimmune diseases. As a key national high-tech enterprise and a national technology innovation exemplary enterprise, Hansoh Pharma has long maintained its position in the top 100 global pharmaceutical enterprises and top 3 China’s Best Industrial Enterprises in the Pharmaceutical R&D Pipeline. The company was listed on the Hong Kong Stock Market (HK03692) in June, 2019.
Hansoh Pharma boasts excellent R&D capabilities and over 20 years of R&D experience. With 1600 professional researchers, we have created an R&D system that covers the entire process from frontier information collection, compound design and screening, pharmacological and toxicological research through to clinical medical research, and established a number of national R&D institutions including the National Enterprise Technology Center, Postdoctoral Research Center, and Key National Laboratory.
Hansoh Pharma is highly efficient in discovering innovative macromolecule and small-molecule drugs, and its R&D efforts cover the fields of monoclonal and bispecific antibodies, ADC, siRNA, and fusion protein products. Hansoh Pharma has so far marketed 7 innovative drugs, and has more than 30 innovative drug programs at different clinical stages with over 50 clinical trials currently in progress, forming a competitive pipeline.
Our innovative drugs on the market include: Saint Luolai (Pegmolesatide Injection）, the only globally-approved EPO mimetic peptide ; Ameile (aumolertinib mesylate tablets), China's first independently-developed third-generation EGFR-TKI; XINYUE (inebilizumab injections), the only global humanized CD19 monoclonal antibody for treating AQP4 antibody-positive NMOSD; Hengmu (tenofovir amibufenamide tablets), China's first independently-developed oral antiviral drug for hepatitis B; Hansoh Xinfu (flumatinib mesylate tablets), China's independently-developed novel second-generation TKI for chronic myeloid leukemia ; Fulaimei (PEG-loxenatide for injection), China's first independently-developed innovative GLP-1RA weekly formulation and the world's first PEGylated GLP-1RA weekly formulation; and Mailingda (morinidazole sodium chloride injection), the world's first innovative nitroimidazole anti-anaerobic drug in 40 years. Seven innovative drugs have been included in the National Reimbursement Drug List, and Hansoh Pharma has successfully transformed itself into an innovative biopharma company.
Hansoh Pharma has always maintained dynamic consistency with global advanced access levels by continuously designing and building production facilities and production lines in accordance with international advanced standards and using advanced production equipment. Our production quality system has been officially certified by FDA in the United States, EMA of the European Union, and PMDA in Japan, and finished preparations and APIs have been approved for marketing in Europe, America, Japan, etc.
Looking ahead, Hansoh Pharma will further deepen its innovation-driven strategy, leverage the global innovation ecosystem, explore and develop more innovative drugs to meet urgent global clinical needs, and make unremitting efforts to improve human health and quality of life.
